Literature DB >> 17301810

A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.

B Yin, M L Tsai, D E Hasz, S K Rathe, M M Le Beau, D A Largaespada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17301810     DOI： 10.1038/sj.leu.2404595

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

2.  Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Authors:  Jatinder K Lamba; Kristine R Crews; Stanley B Pounds; Xueyuan Cao; Varsha Gandhi; William Plunkett; Bassem I Razzouk; Vishal Lamba; Sharyn D Baker; Susana C Raimondi; Dario Campana; Ching-Hon Pui; James R Downing; Jeffrey E Rubnitz; Raul C Ribeiro
Journal:  Pharmacogenomics       Date:  2011-03       Impact factor: 2.533

3.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

Review 4.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

5.  A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.

Authors:  Bin Yin; Ruud Delwel; Peter J Valk; Margaret R Wallace; Mignon L Loh; Kevin M Shannon; David A Largaespada
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

6.  An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Authors:  Klaus H Metzeler; Manuela Hummel; Clara D Bloomfield; Karsten Spiekermann; Jan Braess; Maria-Cristina Sauerland; Achim Heinecke; Michael Radmacher; Guido Marcucci; Susan P Whitman; Kati Maharry; Peter Paschka; Richard A Larson; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Wolfgang Hiddemann; Stefan K Bohlander; Christian Buske
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

Review 7.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

8.  Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Authors:  A Valencia; E Masala; A Rossi; A Martino; A Sanna; F Buchi; F Canzian; D Cilloni; V Gaidano; M T Voso; O Kosmider; M Fontenay; A Gozzini; A Bosi; V Santini
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.